Last reviewed · How we verify

anti-CD7 CAR-pNK cells

PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Phase 1 active Biologic

anti-CD7 CAR-pNK cells is a Biologic drug developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd.. It is currently in Phase 1 development. Also known as: chimeric antigen receptor NK cells with specificity for CD7.

At a glance

Generic nameanti-CD7 CAR-pNK cells
Also known aschimeric antigen receptor NK cells with specificity for CD7
SponsorPersonGen BioTherapeutics (Suzhou) Co., Ltd.
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about anti-CD7 CAR-pNK cells

What is anti-CD7 CAR-pNK cells?

anti-CD7 CAR-pNK cells is a Biologic drug developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd..

Who makes anti-CD7 CAR-pNK cells?

anti-CD7 CAR-pNK cells is developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd. (see full PersonGen BioTherapeutics (Suzhou) Co., Ltd. pipeline at /company/persongen-biotherapeutics-suzhou-co-ltd).

Is anti-CD7 CAR-pNK cells also known as anything else?

anti-CD7 CAR-pNK cells is also known as chimeric antigen receptor NK cells with specificity for CD7.

What development phase is anti-CD7 CAR-pNK cells in?

anti-CD7 CAR-pNK cells is in Phase 1.

Related